Ipsen’s Onivyde Hits Bullseye In Pivotal First-Line Pancreatic Cancer Trial

But Observers Waiting To Raise Sales Projections

 
• By Ayisha Sharma
  
Arrow hitting the bullseye on an archery board
Onivyde Is Set For A Label Expansion For Untreated Pancreatic Cancer • Source: Shutterstock

More from Clinical Trials

More from R&D